Advocacy groups form a buyer’s club to obtain generic versions of Vertex cystic fibrosis drug

What's new in pharma

October 24, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Dado Galdieri/The New York Times STAT+ | Advocacy groups form a buyer's club to obtain generic versions of pricey Vertex cystic fibrosis drug The generic version will be made by Bangladesh's Beximco and will be priced at $6,375 for a child and $12,750 for an adult per year By Ed Silverman STAT+ | How the first nine drug companies won priority review vouchers from Marty Makary's FDA The winners include a gene therapy for a rare form of deafness, a plant-based drug for vaping addiction, and ketamine. By Lizzy Lawrence At a gathering of biopharma executives, a moment of wonder — and also of worry The STAT Summit in Boston made clear the drug industry confronts an era of innovation in the shadow of concerns about public trust and pricing. By Matthew Herper Adobe STAT+ | Ro wants to measure 'food noise' in obesity care Today's biotech news includes: Ro's plan to measure 'food noise' in obesity care, the FDA's split decision on GSK's Blenrep, and more. By Elaine Chen STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser